Published in Medical Letter on the CDC and FDA, December 10th, 2006
Gross profit for the second quarter increased to $69.4 million, up $7.1 million, or 11% over the prior year's quarter, due primarily to higher Ther-Rx sales which represented 42% of overall revenues versus 35% for the second quarter of fiscal 2006.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.